27 September 2022

Re: Clinical Trial Posting results

Product:	ALXN1830
Protocol number	ALXN1830-WAI-202
EudraCT number	2021-001211-90
Protocol title	A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA)
Sponsor:	Alexion Pharmaceuticals Incorporated, USA
EU legal representative:	Alexion Europe SAS, France

Reference is made to ALXN1830-WAI-202 study for ALXN1830, a humanized, affinity-matured IgG4-kappa monoclonal antibody targeted against the neonatal Fc receptor (FcRn).

The global end of trial for Study ALXN1830-WAI-202 occurred on 18 Jan 2022 as a part of Alexion's decision to terminate the ALXN1830 program. This decision was based on data demonstrating challenges with the investigational candidate which impacted the development timelines and commercialization opportunity. No significant safety findings have been identified in the clinical data to date.

No subjects were enrolled in this study globally. As a result, no clinical study results are available.

I trust that you will find the documentation satisfactory. Please do not hesitate to contact me should you require any further information.

Yours faithfully,

Alexion Europe SAS
Tel : +33630132746
e-mail : ClinicalTrials.EU@alexion.com